Results 221 to 230 of about 957,553 (357)

The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database. [PDF]

Cancer Med, 2023
Koguchi T, Naito S, Hatakeyama S, Numakura K, Muto Y, Kato R, Kojima T, Kawasaki Y, Morozumi K, Kandori S, Kawamura S, Nishiyama H, Ito A, Habuchi T, Obara W, Ohyama C, Tsuchiya N, Kojima Y.   +17 more
europepmc   +1 more source

Overcoming Resistance in Cancer Therapy: Computational Exploration of PIK3CA Mutations, Unveiling Novel Non-Toxic Inhibitors, and Molecular Insights Into Targeting PI3Kα

Ilham Kandoussi, Ghyzlane EL Haddoumi, Mariam Mansouri, Lahcen Belyamani, Azeddine Ibrahimi, Rachid Eljaoudi   +5 more
openalex   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

[Molecular targeted therapy for progressive low-grade gliomas in children]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Sun YL, Li M, Liu JJ, Gao WC, Wu YF, Wan LL, Ren SQ, DU SX, Wu WS, Sun LM.   +9 more
europepmc   +1 more source

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome. [PDF]

Int J Mol Sci, 2021
Lee P, Yim R, Yung Y, Chu HT, Yip PK, Gill H.   +5 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Fournier's Gangrene in the Course of Treatment of Advanced Hepatocellular Carcinoma with Molecular-targeted Therapy. [PDF]

Intern Med
Komeda Y, Nagamatsu S, Kaya D, Sueki A, Yamamoto C, Ohta K, Matsuo Y, Nishio Y, Kikukawa S, Matsuura K, Matsuo H, Uejima M, Moriya K.   +12 more
europepmc   +1 more source

Editorial: Molecular Targeted Therapy in Oncology: Lessons From Pharmacogenetics and Pharmacoepigenetics. [PDF]

Front Mol Biosci, 2022
Imani S, Becatti M, Khan MA.
europepmc   +1 more source

PL3-04: Advances in molecular targeted therapies [PDF]

, 2007
Giuseppe Giaccone
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source